Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis (Q46832650)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 December 2007

Language	Label	Description	Also known as
English	Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis	scientific article published on 5 December 2007

Statements

scholarly article

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis (English)

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

0 references

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

author name string

Josie Haydée L Ferreira

1

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

Luciana Girotto Gentil

2

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

Suzana Souza Dias

3

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

Carlos Eduardo C Fedeli

4

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

Simone Katz

5

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

Clara Lúcia Barbiéri

6

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

language of work or name

0 references

publication date

5 December 2007

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

26

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

5

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

677-685

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

The strange case of Leishmania chagasi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

The reemergence of visceral leishmaniasis in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

HIV-associated visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Immunization with recombinant LD1 antigens protects against experimental leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

BCG Expressing LCR1 of Leishmania chagasi Induces Protective Immunity in Susceptible Mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

A Heterologous Prime‐Boost Vaccination Regimen Using ORFF DNA and Recombinant ORFF Protein Confers Protective Immunity against Experimental Visceral Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Identification of a 30 kDa antigen from leishmania (L.) chagasi amastigotes implicated in protective cellular reponses in a murine model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Recombinant cysteine proteinase from Leishmania (Leishmania) chagasi implicated in human and dog T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Lysosomal depletion in macrophages from spleen and foot lesions of Leishmania-infected hamster

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Immunobiological studies on experimental visceral leishmaniasis. III. Cytokine-mediated regulation of parasite replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Leishmania infantum: mixed T-helper-1/T-helper-2 immune response in experimentally infected BALB/c mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Interleukin 10 production correlates with pathology in human Leishmania donovani infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

IL-10 mediates susceptibility to Leishmania donovani infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-γ production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Infection of a canine macrophage cell line with leishmania infantum: determination of nitric oxide production and anti-leishmanial activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Nitric oxide production by macrophages of dogs vaccinated with killed Leishmania infantum promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Inducible nitric oxide synthase and nitric oxide production in Leishmania infantum-infected human macrophages stimulated with interferon-gamma and bacterial lipopolysaccharide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Gene vaccination with naked plasmid DNA: mechanism of CTL priming

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

CD8(+) T cells with parasite-specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Function of CD8+ T lymphocytes in a self-curing mouse model of visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Immunity and immunosuppression in experimental visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Immunopathogenesis of infection with the visceralizing Leishmania species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.044

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.11.044

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/18160187

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46832650&oldid=2133999527"